Table 3. Univariate Cox proportional hazards regression analysis for the overall survival and relapse-free survival of CRC patients.
| Characteristics | No. | OS | RFS | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| Age, years, ≥70 (vs. <70) | 121/224 | 1.935 (0.840–4.454) | 0.121 | 1.680 (0.858–3.291) | 0.130 | |
| Sex, female (vs. male) | 97/224 | 0.734 (0.327–1.650) | 0.455 | 1.170 (0.616–2.222) | 0.632 | |
| Tumor site, left colon (vs. right colon) | 151/224 | 0.647 (0.297–1.410) | 0.274 | 0.794 (0.411–1.536) | 0.493 | |
| Histologic grade, moderated (vs. well) | 193/224 | 0.190 (0.069–0.523) | 0.001 | 0.652 (0.199–2.131) | 0.479 | |
| High TIL (inter + high) (vs. low) | 144/224 | 0.677 (0.312–1.466) | 0.322 | 0.427 (0.225–0.809) | 0.009 | |
| CEA elevation (vs. normal range) | 56/224 | 2.648 (1.209–5.800) | 0.015 | 1.815 (0.907–3.632) | 0.092 | |
| CA19-9 elevation (vs. normal range | 31/224 | 6.890 (3.164–15.006) | <0.001 | 4.860 (2.456–9.616) | <0.001 | |
| pT category, pT4 (vs. pT1–pT3) | 36/224 | 4.501 (2.063–9.818) | <0.001 | 4.331 (2.230–8.413) | <0.001 | |
| pN stage, pN1 & pN2 (vs. pN0) | 97/224 | 2.623 (1.169–5.886) | 0.019 | 5.152 (2.435–10.899) | <0.001 | |
| Distant metastasis, presence (vs. absence) | 52/224 | 4.886 (2.241–10.651) | <0.001 | 30.143 (12.515–72.603) | <0.001 | |
| Stage, ≥ III & IV (vs. I & II) | 95/224 | 2.758 (1.229–6.190) | 0.014 | 4.025 (1.994–8.124) | <0.001 | |
| PD-L1, positive (vs. negative | 23/224 | 0.955 (0.310–3.453) | 0.955 | 0.391 (0.094–1.629) | 0.197 | |
| PIK3CA, mutated (vs. wild-type) | 48/224 | 1.402 (0.589–3.337) | 0.446 | 0.304 (0.093–0.988) | 0.048 | |
CA19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; CRC, colorectal cancer; HR, hazard ratio; OS, overall survival; PD-L1, programmed death ligand-1; RFS, relapse-free survival; TILs, tumor infiltrating lymphocytes.